WF.WKY-(D5Uwm76-D5Uwm61)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
40 |
4.2 |
null |
0.4 |
2.53 |
in vivo visual assessment |
0.0 |
0 |
70297 |
653 |
WF.WKY-(D5Uwm76-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
4.8 |
null |
0.4 |
3.05 |
in vivo visual assessment |
0.0 |
0 |
70304 |
653 |
WF.WKY-(D5Uwm85-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
51 |
3.9 |
null |
0.3 |
2.14 |
in vivo visual assessment |
0.0 |
0 |
70310 |
653 |
WF.WKY-(D5Uwm88-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
6.9 |
null |
0.6 |
4.57 |
in vivo visual assessment |
0.0 |
0 |
70308 |
653 |
WF.WKY-(D5Uwm67-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
35 |
3.2 |
null |
0.4 |
2.37 |
in vivo visual assessment |
0.0 |
0 |
70296 |
653 |
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
41 |
8.1 |
null |
0.6 |
3.84 |
in vivo visual assessment |
0.0 |
0 |
70307 |
653 |
WF.WKY-(D5Uwm78-D5Uwm93)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
27 |
5.0 |
null |
0.5 |
2.6 |
in vivo visual assessment |
0.0 |
0 |
70306 |
653 |
WF.WKY-(D5Uwm82-D5Uwm91)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
3.4 |
null |
0.3 |
2.28 |
in vivo visual assessment |
0.0 |
0 |
70312 |
653 |
WF.WKY-(D5Uwm77-D5Uwm91)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
12 |
3.8 |
null |
0.8 |
2.77 |
in vivo visual assessment |
0.0 |
0 |
70313 |
653 |
WF.WKY-(D5Uwm78-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
32 |
2.8 |
null |
0.3 |
1.7 |
in vivo visual assessment |
0.0 |
0 |
70301 |
653 |
WF.WKY-(D5Uwm76-D5Got18)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
27 |
3.5 |
null |
0.4 |
2.08 |
in vivo visual assessment |
0.0 |
0 |
70300 |
653 |
WF.WKY-(D5Uwm67-D5Uwm81)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
26 |
8.3 |
null |
0.7 |
3.57 |
in vivo visual assessment |
0.0 |
0 |
70303 |
653 |
WF.WKY-(D5Uwm95-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
36 |
7.4 |
null |
0.6 |
3.6 |
in vivo visual assessment |
0.0 |
0 |
70302 |
653 |
WF.WKY-(D5Uwm76-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
26 |
3.8 |
null |
0.4 |
2.04 |
in vivo visual assessment |
0.0 |
0 |
70298 |
653 |
WF.WKY-(D5Uwm87-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
56 |
6.3 |
null |
0.4 |
2.99 |
in vivo visual assessment |
0.0 |
0 |
70309 |
653 |
WF.WKY-(D5Uwm67-D5Uwm78)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
32 |
8.6 |
null |
0.8 |
4.53 |
in vivo visual assessment |
0.0 |
0 |
70299 |
653 |
WF.WKY-(D5Uwm82-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
18 |
2.6 |
null |
0.6 |
2.55 |
in vivo visual assessment |
0.0 |
0 |
70311 |
653 |
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
29 |
8.8 |
null |
0.7 |
3.77 |
in vivo visual assessment |
0.0 |
0 |
70305 |
653 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
46 |
7.9 |
null |
0.5 |
3.39 |
in vivo visual assessment |
0.0 |
0 |
70314 |
653 |